, Tracking Stock Market Picks
Enter Symbol:
Immunogen, Inc. (IMGN) [hlAlert]

down 12.39 %

Immunogen, Inc. (IMGN) rated Buy with price target $19 by ROTH Capital

Posted on: Monday,  Aug 26, 2013  9:25 AM ET by Roth Capital

Roth Capital rated Buy Immunogen, Inc. (NASDAQ: IMGN) on 08/26/2013, when the stock price was $16.30. Since
then, Immunogen, Inc. has lost 12.39% as of 01/08/2016's recent price of $14.28.
If you would have followed this Roth Capital's recommendation on IMGN, you would have lost 12.39% of your investment in 865 days.

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/26/2013 9:25 AM Buy
16.30 19.00
as of 12/13/2013
1 Week down  -4.07 %
1 Month down  -1.64 %
3 Months down  -19.14 %
1 YTD down  -11.90 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy